-
1
Transarterial chemoembolization (TACE) is a primary treatment for unresectable liver cancer, yet survival outcomes vary significantly among patients.
-
2
In a study of 185 patients, the median overall survival after TACE was 28 months, with a 12-month survival rate of 76.4%.
-
3
Independent factors predicting worse overall survival included larger tumor size, portal vein tumor thrombosis, and elevated alpha-fetoprotein levels.
-
4
A new prognostic model was developed, integrating tumor burden and liver function, showing good discrimination for survival prediction.
-
5
The study emphasizes the importance of patient selection and timely treatment adjustments to improve outcomes after TACE.
